Lavakumar Karyampudi – VJRegenMed

Improving cell therapy manufacturing capabilities

Simon Ng — Thu, 17 Feb 2022 12:04:58 +0000

Lavakumar Karyampudi, PhD, Moffitt Cancer Center, Tampa, FL, discusses key challenges and bottlenecks associated with the development of novel cell therapies. Shortening manufacturing times is a priority for producers, where an increased turnaround of therapies will benefit patients. In the field of genetically edited T-cell products that utilize viral vectors, there is an increased demand for contract development and manufacturing company (CDMO) to manufacture the viral vectors. This interview took place at Advanced Therapies Week 2022.

Key developments in the future of advanced therapies

Simon Ng — Tue, 01 Feb 2022 18:03:39 +0000

Lavakumar Karyampudi, PhD, Moffitt Cancer Center, Tampa, FL, provides an overview of the topics discussed during the session on cell and gene therapies of the future at Advanced Therapies Week 2022. Dr Karyampudi highlights the development of hematopoietic stem cell gene therapy for rare disease, optimizing the yield of lentiviral vectors for gene therapies, as well as strategies to decrease manufacturing times in the production of cell and gene therapies. This interview took place at Advanced Therapies Week 2022.

Advances in cell therapies by the Cell Therapies Core

Simon Ng — Tue, 01 Feb 2022 18:03:36 +0000

Lavakumar Karyampudi, PhD, Moffitt Cancer Center, Tampa, FL, describes some of the research conducted at the Cell Therapies Core (CTC) at Moffitt Cancer Center. Various cell therapies are under investigation, including tumor-infiltrating lymphocyte (TIL) and autologous chimeric antigen receptor (CAR) T-cell therapies. The center additionally works with companies in early-stage clinical trials and to streamline manufacturing processes, and providing guidance on Chemistry, Manufacturing and Controls (CMC). This interview took place at Advanced Therapies Week 2022.